NCT04232280View on ClinicalTrials.gov

Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy Adults

PHASE2CompletedINTERVENTIONAL
Enrollment

315

Participants

Timeline

Start Date

January 9, 2020

Primary Completion Date

January 4, 2023

Study Completion Date

January 4, 2023

Conditions
Cytomegalovirus Infection
Interventions
BIOLOGICAL

mRNA-1647

Lyophilized product that is reconstituted with saline then diluted with a special diluent to reach the desired concentration

OTHER

Placebo

0.9% sodium chloride (normal saline) injection

Trial Locations (9)

40509

Alliance for Multispecialty Research, Lexington

61614

Optimal Research, Peoria

66219

Johnson County Clin-Trials, Lenexa

77901

Crossroads Clinical Research, Victoria

78745

Tekton Research Inc, Austin

84109

Foothill Family Clinic, Salt Lake City

84121

Foothill Family Clinic-South Clinic, Salt Lake City

95864

Benchmark Research, Sacramento

43213-6523

Aventiv Research Inc, Columbus

All Listed Sponsors
lead

ModernaTX, Inc.

INDUSTRY

NCT04232280 - Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy Adults | Biotech Hunter | Biotech Hunter